Baseline | Follow-up | |||||
E* | NE† | RR (95% CI)‡ | E* | NE† | RR (95% CI)‡ | |
Lower respiratory tract symptoms§ | 39% | 32% | 1.3 (1.0 to 1.7) | 35% | 28% | 1.4 (1.1 to 1.9) |
Nasal symptoms¶ | 40% | 24% | 1.7 (1.3 to 2.3) | 35% | 29% | 1.2 (0.9 to 1.6) |
Inhaled medication | 14% | 5% | 2.8 (1.4 to 5.8) | 20% | 13% | 1.5 (1.0 to 2.4) |
Oral medication | 17% | 10% | 1.7 (1.0 to 2.8) | 17% | 13% | 1.5 (1.0 to 2.4) |
↵* Prevalence among exposed individuals (n=466).
↵† Prevalence among non-exposed individuals (n=156).
↵‡ Relative risks and 95% CIs for exposed versus non-exposed, adjusted for sex, age and smoking status.
↵§ Wheeze with breathlessness, wheeze apart from colds, nocturnal attacks of shortness of breath, chronic cough and/or chronic phlegm.
↵¶ A problem with sneezing or a runny or a blocked nose when not having a cold or the flu in the last 12 months.